|
1
|
Kobayashi T, Masaki T, Kogawa K, Matsuoka
H and Sugiyama M: Efficacy of gum chewing on bowel movement after
open colectomy for left-sided colorectal cancer: A randomized
clinical trial. Dis Colon Rectum. 58:1058–1063. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Karoui M, Rullier A, Luciani A, Bonnetain
F, Auriault ML, Sarran A, Monges G, Trillaud H, Le Malicot K, Leroy
K, et al: Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab
versus immediate surgery for high-risk stage II and III colon
cancers: A multicentre randomised controlled phase II trial-the
PRODIGE 22-ECKINOXE trial. BMC Cancer. 15:5112015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nuñez-Sánchez MA, García-Villalba R,
Monedero-Saiz T, García-Talavera NV, Gómez-Sánchez MB,
Sánchez-Álvarez C, García-Albert AM, Rodríguez-Gil FJ, Ruiz-Marín
M, Pastor-Quirante FA, et al: Targeted metabolic profiling of
pomegranate polyphenols and urolithins in plasma, urine and colon
tissues from colorectal cancer patients. Mol Nutr Food Res.
58:1199–1211. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kaufman HL, Kim DW, Kim-Schulze S,
DeRaffele G, Jagoda MC, Broucek JR and Zloza A: Results of a
randomized phase I gene therapy clinical trial of nononcolytic
fowlpox viruses encoding T cell costimulatory molecules. Hum Gene
Ther. 25:452–460. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
André T, de Gramont A, Vernerey D,
Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T,
Tabernero J, Van Laethem JL, et al: Adjuvant fluorouracil,
leucovorin, and oxaliplatin in stage II to III colon cancer:
Updated 10-year survival and outcomes according to BRAF mutation
and mismatch repair status of the MOSAIC study. J Clin Oncol.
33:4176–4187. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hussmann M, Janke K, Kranz P, Neumann F,
Mersch E, Baumann M, Goepelt K, Brockmeier U and Metzen E:
Depletion of the thiol oxidoreductase ERp57 in tumor cells inhibits
proliferation and increases sensitivity to ionizing radiation and
chemotherapeutics. Oncotarget. 6:39247–39261. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Apostolou P, Toloudi M, Kourtidou E,
Mimikakou G, Vlachou I, Chatziioannou M and Papasotiriou I: Use of
the comet assay technique for quick and reliable prediction of in
vitro response to chemotherapeutics in breast and colon cancer. J
Biol Res (Thessalon). 21:142014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kozovska Z, Gabrisova V and Kucerova L:
Colon cancer: Cancer stem cells markers, drug resistance and
treatment. Biomed Pharmacother. 68:911–916. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liang L and Huang J: Oxymatrine inhibits
epithelial-mesenchymal transition through regulation of NF-kappaB
signaling in colorectal cancer cells. Oncol Rep. 36:1333–1338.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mladenova D, Pangon L, Currey N, Ng I,
Musgrove EA, Grey ST and Kohonen-Corish MR: Sulindac activates
NF-kappaB signaling in colon cancer cells. Cell Commun Signal.
11:732013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang S, Zhai C, Zhang Y, Yu Y, Zhang Y, Ma
L, Li S and Qiao Y: Cardamonin, a novel antagonist of hTRPA1 cation
channel, reveals therapeutic mechanism of pathological pain.
Molecules. 21:pii: E1145. 2016. View Article : Google Scholar
|
|
12
|
Niu PG, Zhang YX, Shi DH, Liu Y, Chen YY
and Deng J: Cardamonin inhibits metastasis of lewis lung carcinoma
cells by decreasing mTOR activity. PLoS One. 10:e01277782015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liao Q, Shi DH, Zheng W, Xu XJ and Yu YH:
Antiproliferation of cardamonin is involved in mTOR on aortic
smooth muscle cells in high fructose-induced insulin resistance
rats. Eur J Pharmacol. 641:179–186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jia D, Tan Y, Liu H, Ooi S, Li L, Wright
K, Bennett S, Addison CL and Wang L: Cardamonin reduces
chemotherapy-enriched breast cancer stem-like cells in vitro and in
vivo. Oncotarget. 7:771–785. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mi XG, Song ZB, Sun LG, Bao YL, Yu CL, Wu
Y and Li YX: Cardamonin inhibited cell viability and tumorigenesis
partially through blockade of testes-specific protease 50-mediated
nuclear factor-kappaB signaling pathway activation. Int J Biochem
Cell Biol. 73:63–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Corvaisier M, Bauzone M, Corfiotti F,
Renaud F, El Amrani M, Monté D, Truant S, Leteurtre E, Formstecher
P, Van Seuningen I, et al: Regulation of cellular quiescence by
YAP/TAZ and cyclin E1 in colon cancer cells: Implication in
chemoresistance and cancer relapse. Oncotarget. 7:56699–56712.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ayeka PA, Bian Y, Mwitari PG, Chu X, Zhang
Y, Uzayisenga R and Otachi EO: Immunomodulatory and anticancer
potential of Gan cao (Glycyrrhiza uralensis Fisch.)
polysaccharides by CT-26 colon carcinoma cell growth inhibition and
cytokine IL-7 upregulation in vitro. BMC Complement Altern Med.
16:2062016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dahl O and Pfeffer F: Twenty-five years
with adjuvant chemotherapy for colon cancer-a continuous evolving
concept. Acta Oncol. 54:1–4. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kang HW, Kim JM, Cha MY, Jung HC, Song IS
and Kim JS: Deguelin, an Akt inhibitor, down-regulates NF-κB
signaling and induces apoptosis in colon cancer cells and inhibits
tumor growth in mice. Dig Dis Sci. 57:2873–2882. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stark LA, Reid K, Sansom OJ, Din FV,
Guichard S, Mayer I, Jodrell DI, Clarke AR and Dunlop MG: Aspirin
activates the NF-kappaB signalling pathway and induces apoptosis in
intestinal neoplasia in two in vivo models of human colorectal
cancer. Carcinogenesis. 28:968–976. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang J, Liu L, Qiu H, Zhang X, Guo W, Chen
W, Tian Y, Fu L, Shi D, Cheng J, et al: Ursolic acid simultaneously
targets multiple signaling pathways to suppress proliferation and
induce apoptosis in colon cancer cells. PLoS One. 8:e638722013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Radhakrishnan EK, Bava SV, Narayanan SS,
Nath LR, Thulasidasan AK, Soniya EV and Anto RJ: [6]-Gingerol
induces caspase-dependent apoptosis and prevents PMA-induced
proliferation in colon cancer cells by inhibiting MAPK/AP-1
signaling. PLoS One. 9:e1044012014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Elkady AI, Hussein RA and El-Assouli SM:
Harmal extract induces apoptosis of HCT116 human colon cancer
cells, mediated by inhibition of nuclear factor-κB and activator
protein-1 signaling pathways and induction of cytoprotective genes.
Asian Pac J Cancer Prev. 17:1947–1959. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ding X, Zhou X, Jiang B, Zhao Q and Zhou
G: Triptolide suppresses proliferation, hypoxia-inducible factor-1α
and c-Myc expression in pancreatic cancer cells. Mol Med Rep.
12:4508–4513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thao NP, Luyen BT, Kim EJ, Kang JI, Kang
HK, Cuong NX, Nam NH, Kiem PV, Minh CV and Kim YH: Steroidal
constituents from the edible sea urchin Diadema savignyi
Michelin induce apoptosis in human cancer cells. J Med Food.
18:45–53. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takaoka Y, Shimizu Y, Hasegawa H, Ouchi Y,
Qiao S, Nagahara M, Ichihara M, Lee JD, Adachi K, Hamaguchi M and
Iwamoto T: Forced expression of miR-143 represses ERK5/c-Myc and
p68/p72 signaling in concert with miR-145 in gut tumors of Apc(Min)
mice. PLoS One. 7:e421372012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kawasaki Y, Komiya M, Matsumura K, Negishi
L, Suda S, Okuno M, Yokota N, Osada T, Nagashima T, Hiyoshi M, et
al: MYU, a Target lncRNA for Wnt/c-Myc signaling, mediates
induction of CDK6 to promote cell cycle progression. Cell Rep.
16:2554–2564. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park S, Gwak J, Han SJ and Oh S:
Cardamonin suppresses the proliferation of colon cancer cells by
promoting β-catenin degradation. Biol Pharm Bull. 36:1040–1044.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Talebi A, Kianersi K and Beiraghdar M:
Comparison of gene expression of SOX2 and OCT4 in normal tissue,
polyps, and colon adenocarcinoma using immunohistochemical
staining. Adv Biomed Res. 4:2342015.PubMed/NCBI
|
|
30
|
Ng WL, Chen G, Wang M, Wang H, Story M,
Shay JW, Zhang X, Wang J, Amin AR, Hu B, et al: OCT4 as a target of
miR-34a stimulates p63 but inhibits p53 to promote human cell
transformation. Cell Death Dis. 5:e10242014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Amini S, Fathi F, Mobalegi J,
Sofimajidpour H and Ghadimi T: The expressions of stem cell
markers: Oct4, Nanog, Sox2, nucleostemin, Bmi, Zfx, Tcl1, Tbx3,
Dppa4, and Esrrb in bladder, colon, and prostate cancer, and
certain cancer cell lines. Anat Cell Biol. 47:1–11. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Song ZB, Bao YL, Zhang Y, Mi XG, Wu P, Wu
Y, Yu CL, Sun Y, Zheng LH, Huang YX, et al: Testes-specific
protease 50 (TSP50) promotes cell proliferation through the
activation of the nuclear factor-κB (NF-κB) signalling pathway.
Biochem J. 436:457–467. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu YL and Sun YN: Down-regulation of
testes-specific protease 50 induces apoptosis in human
laryngocarcinoma HEp2 cells in a NF-κB-mediated pathway. Mol Biol
Rep. 41:7743–7747. 2014. View Article : Google Scholar : PubMed/NCBI
|
